News Drug Development

Roche’s MabThera Hits Targets in Two Trials

January 25, 2008 |

1 min read

DAVOS, Jan 25 (Reuters) - Roche’s cancer drug MabThera met its main goals in two late-stage clinical trials, showing benefits in adult leukaemia and rheumatoid arthritis, the Swiss drugmaker said on Friday.

Clinical research Phase III Europe

Roche

MORE ON THIS TOPIC

Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.

Prostate cancer

Candel Stock Skyrockets on Promising Phase III Prostate Cancer Data

December 12, 2024

·

3 min read

·

Tristan Manalac

Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.

Immunology and inflammation

Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data

December 11, 2024

·

2 min read

·

Tristan Manalac

Medical technology. Doctor holding health icon with dna, electronic medical record. Digital healthcare and research with global network connection on hologram virtual screen, insurance, digital health technology

Partnered

Ending the Diagnostic Odyssey for Patients

December 11, 2024

·

4 min read

·

BioSpace Insights

Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.

CAR-T

J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data

December 11, 2024

·

2 min read

·

Tristan Manalac